<DOC>
	<DOCNO>NCT02644278</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability VX-984 administer alone combination pegylated liposomal doxorubicin ( PLD ) , determine maximum tolerate dose ( MTD ) preliminary evidence efficacy VX-984 combination PLD subject advanced solid tumor</brief_summary>
	<brief_title>First-in-Human Study Safety , Tolerability , Pharmacokinetic/Pharmacodynamic Profile VX-984 Combination With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Subjects ( male female Part A female Part B ) least 18 year age . Part A Subjects histologically cytologically confirm malignant advance solid tumor , progress least 1 prior chemotherapy , either 1 . No standard care available 2 . PLD dose schedule use might consider standard care Part B 1 . Subjects histologically confirm advanced primary endometrial cancer ( locally advance incurable endometrial cancer treat surgery and/or radiation ineligible treatment ) , recurrent metastatic endometrial cancer , 2 . Completed 1 line chemotherapy treatment platinumcontaining regimen advance set Measurable disease accord RECIST criterion ( Version 1.1 ) Life expectancy least 12 week Hematological biochemical index within acceptable range show screen . Normal leave ventricular ejection fraction screen assessed transthoracic echocardiogram multiple gated acquisition ( MUGA ) scan Previous radiotherapy ( unless brachytherapy ) , endocrine therapy , chemotherapy , exposure investigational medicinal product 4 week ( 6 week nitrosoureas MitomycinC ) 4 drug halflives plan administration first dose study drug , whichever great . Previous immunotherapy 4 week plan administration first dose study drug . For Part B : 1 . Subjects uterine carcinosarcoma 2 . Prior anthracycline therapy 3 . More 1 prior chemotherapy regimen ( subject receive first line carboplatin taxane receive taxane second line consider 1 prior chemotherapy regimen ) Unresolved toxicity Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 great previous anticancer therapy radiotherapy History spinal cord compression brain metastasis , unless asymptomatic , treated , stable , require treatment steroid least 4 week plan administration first dose study drug . Any history leptomeningeal metastasis . Female subject pregnant lactate Screening , plan become pregnant study within 6 month last dose study drug Female subject childbearing potential must adhere contraception guideline outline protocol . Female subject consider nonchildbearing potential undergone surgical hysterectomy bilateral oophorectomy amenorrheic 2 year screen serum folliclestimulating hormone ( FSH ) level within laboratory 's reference range postmenopausal females Male subject pregnant lactate partner partner plan become pregnant study within 6 month plan administration last dose study drug Major surgery â‰¤4 week first dose study drug , incomplete recovery prior major surgical procedure Cardiac condition Prior bone marrow transplant Extensive radiotherapy ( great 15 % bone marrow ) Any condition investigator 's opinion would make subject good candidate clinical study , Part B : Current active malignancy type , exception adequately treat conebiopsied situ carcinoma cervix uteri basal squamous cell carcinoma skin . Prior cancer remission 2 year would exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>